| scholarly article | Q13442814 |
| P50 | author | Hong Liang | Q37384912 |
| Christophe Baudouin | Q37616711 | ||
| Françoise Brignole-Baudouin | Q57417138 | ||
| P2093 | author name string | Luisa Riancho | |
| Aude Pauly | |||
| P2860 | cites work | Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. | Q33202369 |
| In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. | Q33217965 | ||
| Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model | Q33488096 | ||
| Preservatives in eyedrops: the good, the bad and the ugly | Q34105511 | ||
| Reconstituted human corneal epithelium: a new alternative to the Draize eye test for the assessment of the eye irritation potential of chemicals and cosmetic products | Q34461968 | ||
| Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. | Q36940995 | ||
| The application of Russell and Burch 3R principle in rodent models of neurodegenerative disease: the case of Parkinson's disease | Q37260722 | ||
| Allergy to ophthalmic preservatives | Q37583780 | ||
| In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line. | Q39993818 | ||
| New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents | Q40545784 | ||
| Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. | Q40968901 | ||
| Occludin gene expression as an early in vitro sign for mild eye irritation assessment | Q43281284 | ||
| Multiple endpoint analysis of the 3D-reconstituted corneal epithelium after treatment with benzalkonium chloride: early detection of toxic damage. | Q44435422 | ||
| The dilution of benzalkonium chloride (BAK) in the tear film. | Q45951823 | ||
| Prevalence of ocular surface disease in glaucoma patients | Q46389257 | ||
| Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. | Q54033336 | ||
| Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term | Q57693379 | ||
| Effects of topical antiglaucoma medications on the ocular surface | Q79387442 | ||
| In vitro assessment of eye irritancy using the Reconstructed Human Corneal Epithelial SkinEthic HCE model: application to 435 substances from consumer products industry | Q84902001 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 869-875 | |
| P577 | publication date | 2011-03-22 | |
| P1433 | published in | British Journal of Ophthalmology | Q13443571 |
| P1476 | title | Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system | |
| P478 | volume | 95 |
| Q46715705 | Acute corneal toxicity of latanoprost with different preservatives |
| Q36385076 | Aliphatic β-nitroalcohols for therapeutic corneoscleral cross-linking: corneal permeability considerations |
| Q39171184 | Cell viability score (CVS) as a good indicator of critical concentration of benzalkonium chloride for toxicity in cultured ocular surface cell lines |
| Q35121491 | Corneal alterations induced by topical application of commercial latanoprost, travoprost and bimatoprost in rabbit |
| Q44649981 | Corneal epithelial cell viability following exposure to ophthalmic solutions containing preservatives and/or antihypertensive agents |
| Q35170366 | Development of a curved, stratified, in vitro model to assess ocular biocompatibility |
| Q91239622 | Effects of sustained daily latanoprost application on anterior chamber anatomy and physiology in mice |
| Q54260729 | Estimation of the in vitro eye irritating and inflammatory potential of lipopolysaccharide (LPS) and dust by using reconstituted human corneal epithelium tissue cultures. |
| Q41472716 | Evaluation of Eye Irritation Potential of Solid Substance with New 3D Reconstructed Human Cornea Model, MCTT HCE(TM). |
| Q96022836 | Evaluation of ocular surface disease in elderly patients with glaucoma: expression of matrix metalloproteinase-9 in tears |
| Q34316383 | Evaluation of protective effects of trehalose on desiccation of epithelial cells in three dimensional reconstructed human corneal epithelium |
| Q34730252 | Excipients of preservative-free latanoprost induced inflammatory response and cytotoxicity in immortalized human HCE-2 corneal epithelial cells |
| Q90216352 | Eye Irritation Potential of Microglycine and Microglycine-Containing Ointments: An in vitro Study on Reconstructed Human Corneal Epithelium |
| Q42040480 | Free radicals and the pH of topical glaucoma medications: a lifetime of ocular chemical injury? |
| Q42703677 | Identification of cornifelin and early growth response-1 gene as novel biomarkers for in vitro eye irritation using a 3D reconstructed human cornea model MCTT HCE™. |
| Q42975877 | In vitro effects of preserved and unpreserved anti-allergic drugs on human corneal epithelial cells. |
| Q91644909 | Medical devices biocompatibility assessment on HCE: Evidences of delayed cytotoxicity of preserved compared to preservative free eye drops |
| Q34708156 | Multiple endpoint analysis of BAC-preserved and unpreserved antiallergic eye drops on a 3D-reconstituted corneal epithelial model. |
| Q89458782 | Myopia Outcome Study of Atropine in Children (MOSAIC): an investigator-led, double-masked, placebo-controlled, randomised clinical trial protocol |
| Q36985297 | Ocular Tolerability of Preservative-Free Tafluprost and Latanoprost: in vitro and in vivo Comparative Study |
| Q37079208 | Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes |
| Q38190054 | Ocular surface cytotoxicity and safety evaluation of tafluprost, a recently developed anti-glaucoma prostaglandin analog |
| Q38843414 | Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK). |
| Q37579359 | Ocular toxicity of benzalkonium chloride homologs compared with their mixtures |
| Q36125697 | Possibilities and limitations of eye drops for glaucoma therapy |
| Q47381165 | Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages. |
| Q39348004 | Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice |
| Q38217464 | Preservative-free latanoprost eye drops in patients with primary open-angle glaucoma/ocular hypertension |
| Q64896322 | Preservatives in glaucoma medication. |
| Q38339962 | Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma |
| Q93110214 | Safety data on in situ gelling bimatoprost loaded nanovesicular formulations |
| Q35444198 | Symptoms and signs of ocular surface disease related to topical medication in patients with glaucoma |
| Q88771690 | [Preoperative therapy switch before glaucoma filtration surgery : Influence of the systemic antiglaucomatous and local antiphlogistic therapy on the intraocular pressure] |
Search more.